No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
4basebio PLC and its affiliated entities are dedicated to the research, development, production, and commercialization of synthetic DNA and RNA compounds, in addition to non-viral vector technologies. Their operations span across Europe, the United States, and other global markets. The company's innovative product portfolio includes: hpDNA: A unique double-stranded linear DNA featuring covalently closed hairpin structures at its ends, suitable for diverse viral and non-viral vector uses. opDNA: This partially opened, linear, double-stranded DNA is specifically engineered for in vitro transcription processes, enabling the generation of mRNA for vaccines and therapeutic applications. oeDNA (open-ended DNA): A linear, double-stranded DNA product optimally suited for advanced genome editing techniques. osDNA (open stabilized DNA): This product integrates specific nucleotide modifications within its DNA backbone, allowing for the precise modulation of its immunostimulatory properties, which is crucial for DNA vaccine development. The Hermes: A proprietary delivery system for nucleic acids and protein payloads, renowned for offering a thermo-stable alternative to conventional lipid-based delivery platforms. Established in 2008 and headquartered in Cambridge, United Kingdom, 4basebio PLC was formerly known as 4basebio UK Societas, adopting its current name in July 2021.
www.4basebio.comNo one on the platform currently holds 88Q.F.
No tracked institution reports a position in 88Q.F as of their last filing.
No one on the platform has traded 88Q.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 81.5% | 29.5% | ||||
| Profit Margin % | -998.5% | -1342.8% | ||||
| Free Cash Flow Margin % | -1017.5% | -1518.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | +67.3% | $-1.17 | $-1.19–$-1.14 | — | 1 |
| 2027 | $14M | +328.6% | $-0.70 | $-0.71–$-0.69 | — | 1 |
| 2028 | $29M | +108.3% | $-0.23 | $-0.24–$-0.23 | — | 1 |
| 2029 | $41M | +40.0% | $0.23 | $0.23–$0.24 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-22 | $-0.68 | $-0.68 | +0.0% |
| 2026-02-25 | $-0.77 | $-0.58 | +24.5% |
| 2023-09-21 | $-0.33 | $-0.29 | +11.0% |